Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection

Antiviral Research

Volumn 97, Issue 3, 2013, Pages 318-328

  Tutykhina, Irina L ^a   Sedova, Elena S ^a   Gribova, Irina Y ^a   Ivanova, Tatiana I ^b   Vasilev, Lev A ^b   Rutovskaya, Marina V ^b   Lysenko, Andrei A ^a   Shmarov, Maxim M ^a   Logunov, Denis Y ^a   Naroditsky, Boris S ^a   Tillib, Sergei V ^b   Gintsburg, Alexander L ^a  

^a GAMALEYA RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY   (Russian Federation)

^b INSTITUTE OF GENE BIOLOGY   (Russian Federation)

Author keywords

Adenoviral vector; Influenza virus; Passive immunization; Single domain antibody

Indexed keywords

ADENOVIRUS VECTOR; ANTI HEMAGGLUTININ FORMATTED NANOBODY; ANTI HEMAGGLUTININ FORMATTED NANOBODY 7; ANTIVIRUS AGENT; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT ADENOVIRUS VECTOR; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA VIRUS; INFLUENZA VIRUS A H5N2; MORTALITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SURVIVAL; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; FEMALE; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION, PASSIVE; INFLUENZA A VIRUS, H5N2 SUBTYPE; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; SINGLE-DOMAIN ANTIBODIES;

ADENOVIRIDAE; MUS; ORTHOMYXOVIRIDAE;

EID: 84873050655     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.12.021     Document Type: Article

References (77)

1. Arbabi Ghahroudi M., Desmyter A., Wyns L., Hamers R., Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997, 414:521-526.
2. Bangari D.S., Mittal S.K. Current strategies and future directions for eluding adenoviral vector immunity. Curr. Gene Ther. 2006, 6:215-226.
3. Bazl M.R., Rasaee M.J., Foruzandeh M., Rahimpour A., Kiani J., Rahbarizadeh F., Alirezapour B., Mohammadi M. Production of chimeric recombinant single domain antibody-green fluorescent fusion protein in Chinese hamster ovary cells. Hybridoma (Larchmt) 2007, 26:1-9.
4. Beer S.J., Matthews C.B., Stein C.S., Ross B.D., Hilfinger J.M., Davidson B.L. Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Ther. 1998, 5:740-746.
5. Brennan F.R., Morton L.D., Spindeldreher S., Kiessling A., Allenspach R., Hey A., Muller P.Y., Frings W., Sims J. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. mAbs 2010, 2:233-255.
6. Campana V., Zentilin L., Mirabile I., Kranjc A., Casanova P., Giacca M., Prusiner S.B., Legname G., Zurzolo C. Development of antibody fragments for immunotherapy of prion diseases. Biochem. J. 2009, 418:507-515.
7. Chiuchiolo M.J., Boyer J.L., Krause A., Senina S., Hackett N.R., Crystal R.G. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J. Infect. Dis. 2006, 194:1249-1257.
8. Croyle M.A., Chirmule N., Zhang Y., Wilson J.M. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 2002, 13:1887-1900.
9. Croyle M.A., Patel A., Tran K.N., Gray M., Zhang Y., Strong J.E., Feldmann H., Kobinger G.P. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008, 3:e3548.
10. Croyle M.A., Yu Q.C., Wilson J.M. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum. Gene Ther. 2000, 11:1713-1722.
11. ElsConrath K., Lauwereys M., Wyns L., Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J. Biol. Chem. 2001, 276:7346-7350.
12. Fisher K.D., Stallwood Y., Green N.K., Ulbrich K., Mautner V., Seymour L.W. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001, 8:341-348.
13. Gabbard J., Velappan N., Di Niro R., Schmidt J., Jones C.A., Tompkins S.M., Bradbury A.R. A humanized anti-M2 scFv shows protective in vitro activity against influenza. Protein Eng., Des. Sel. 2009, 22:189-198.
14. Ghassabeh G.H., Muyldermans S., Saerens D. Current Trends in Monoclonal Antibody Development and Manufacturing 2010, 29-48. Springer, New York. S.J. Shire (Ed.).
15. Giorgini A., Brown H.J., Lock H.R., Nimmerjahn F., Ravetch J.V., Verbeek J.S., Sacks S.H., Robson M.G. Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. J. Immunol. 2008, 181:8745-8752.
16. Greenberg A.S., Avila D., Hughes M., McKinney E.C., Flajnik M.F. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 1996, 374:168-173.
17. Gribova I.Y., Tillib S.V., Tutykhina I.L., Shmarov C.E., Logunov D.Y., Verkhovskaya L.V., Naroditskii B.S., Gintsburg A.L. Effective genetic expression of nanoantibodies by recombinant adenoviral vector in vitro. Acta Naturae 2011, 3:64-70.
18. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Bendahman N., Hamers R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
19. Harbury P.B., Zhang T., Kim P.S., Alber T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 1993, 262(5138):1401-1407.
20. Harmsen M.M., Van Solt C.B., Fijten H.P., Van Setten M.C. Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. Vaccine 2005, 23:4926-4934.
21. Harmsen M.M., De Haard H.J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 2007, 77:13-22.
22. Health Protection Agency, 2011. Pharmacological treatment and prophylaxis of influenza. Version 1.7. Available from:, (Accessed July 2012). http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1287147812045.
23. Hensley S.E., Das S.R., Bailey A.L., Schmidt L.M., Hickman H.D., Jayaraman A., Viswanathan K., Raman R., Sasisekharan R., Bennink J.R., Yewdell J.W. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 2009, 326:734-736.
24. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23:1126-1136.
25. Hultberg A., Temperton N.J., Rosseels V., Koenders M., Gonzalez-Pajuelo M., Schepens B., Ibañez L.I., Vanlandschoot P., Schillemans J., Saunders M., Weiss R.A., Saelens X., Melero J.A., Verrips C.T., Van Gucht S., de Haard H.J. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS One 2011, 6(4):e17665.
26. Ibañez L.I., De Filette M., Hultberg A., Verrips T., Temperton N., Weiss R.A., Vandevelde W., Schepens B., Vanlandschoot P., Saelens X. Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. J. Infect. Dis. 2011, 203:1063-1072.
27. Kaminski D.A., Lee F.E. Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design. Front. Immunol. 2011, 2:1-14.
28. Kasuya K., Boyer J.L., Tan Y., Alipui D.O., Hackett N.R., Crystal R.G. Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody. Mol. Ther. 2005, 11:237-244.
29. Kesser B.W., Hashisaki G.T., Holt J.R. Gene transfer in human vestibular epithelia and the prospects for inner ear gene therapy. Laryngoscope 2008, 118:821-831.
30. Khurana S., Verma S., Verma N., Crevar C.J., Carter D.M., Manischewitz J., King L.R., Ross T.M., Golding H. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J. Virol. 2011, 85:1246-1256.
31. Kita Y., Nogimura H., Ida M., Ozawa Y., Kageyama Y., Ohi S., Ito Y., Matsushita K., Takahashi T., Suzuki K., Kazui T., Hayashi S., Enosawa S., Li X.K., Suzuki S. Time course of gene expression after the injection of adenoviral vectors containing CTLA4IG gene. Transplant. Proc. 2004, 36:2443-2445.
32. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
33. Krammer F., Pica N., Hai R., Tan G.S., Palese P. Hemagglutinin stalk reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J. Virol. 2012, 10.1128/JVI.01336-12.
34. Kumaki Y., Ennis J., Rahbar R., Turner J.D., Wandersee M.K., Smith A.J., Bailey K.W., Vest Z.G., Madsen J.R., Li J.K.-K., Barnard D.L. Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. Antiviral. Res. 2011, 89:75-82.
35. Lasaro M.O., Ertl H.C. New insights on adenovirus as vaccine vectors. Mol. Ther. 2009, 17:1333-1339.
36. Lo C.Y., Wu Z., Misplon J.A., Price G.E., Pappas C., Kong W.P., Tumpey T.M., Epstein S.L. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 2008, 26:2062-2072.
37. Luke T.C., Casadevall A., Watowich S.J., Hoffman S.L., Beigel J.H., Burgess T.H. Hark back: passive immunotherapy for influenza and other serious infections. Crit. Care Med. 2010, 38:66-73.
38. Mabry R., Rani M., Geiger R., Hubbard G.B., Carrion R.J., Brasky K., Patterson J.L., Georgiou G., Iverson B.L. Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect. Immunol. 2005, 73:8362-8368.
39. McGuire L.W., Redden W.R. The use of convalescent human serum in influenza pneumonia-a preliminary report. Am. J. Public Health 1918, 8:741-744.
40. Mossad S.B. Influenza in long-term care facilities: preventable, detectable, treatable. Cleve. Clin. J. Med. 2009, 76:513-521.
41. Musana K.A., Yale S.H., Mazza J.J., Reed K.D. Practical considerations to influenza vaccination. Clin. Med. Res. 2004, 2:256-259.
42. Muyldermans S., Baral T.N., Retamozzo V.C., et al. Vet. Immunol. Immunopathol. 2009, 128:178-183.
43. Nguyen V.K., Desmyter A., Muyldermans S. Functional heavy-chain antibodies in Camelidae. Adv. Immunol. 2001, 79:261-296.
44. Nuttall S.D., Krishnan U.V., Hattarki M., De Gori R., Irving R.A., Hudson P.J. Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol. Immunol. 2001, 38:313-326.
45. O'Donnell C.D., Vogel L., Wright A., Das S.R., Wrammert J., Li G.M., McCausland M., Zheng N.Y., Yewdell J.W., Ahmed R., Wilson P.C., Subbarao K. Antibody pressure by a human monoclonal antibody targeting the 2009 pandemic H1N1 virus hemagglutinin drives the emergence of a virus with increased virulence in mice. mBio 2012, 3:1-10.
46. Okuno Y., Matsumoto K., Isegawa Y., Ueda S. Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J. Virol. 1994, 68:517-520.
47. Peterson E., Owens S.M., Henry R.L. Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse. AAPS J. 2006, 8:383-390.
48. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoint. Am. J. Hyg. 1938, 27:493-497.
49. Rudneva I., Ignatieva A., Timofeeva T., Shilov A., Kushch A., Masalova O., Klimova R., Bovin N., Mochalova L., Kaverin N. Escape mutants of pandemic influenza A/H1N1 2009 virus: variations in antigenic specificity and receptor affinity of the hemagglutinin. Virus Res. 2012, 166:61-67.
50. Saerens D., Kinne J., Bosmans E., Wernery U., Muyldermans S., ElsConrath K. Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J. Biol. Chem. 2004, 279:51965-51972.
51. Segura M.M., Alba R., Bosch A., Chillón M. Advances in helper-dependent adenoviral vector research. Curr. Gene Ther. 2008, 8:222-235.
52. Shiraishi T., Suzuyama K., Okamoto H., Mineta T., Tabuchi K., Nakayama K., Shimizu Y., Tohma J., Ogihara T., Naba H., Mochizuki H., Nagata S. Increased cytotoxicity of soluble Fas ligand by fusing isoleucine zipper motif. Biochem. Biophys. Res. Commun. 2004, 322(1):197-202.
53. Shirakawa T. Clinical trial design for adenoviral gene therapy products. Drug News Perspect. 2009, 22:140-145.
54. Shmarov M.M., Sedova E.S., Verkhovskaya L.V., Rudneva I.A., Bogacheva E.A., Barykova Y.A., Shcherbinin D.N., Lysenko A.A., Tutykhina I.L., Logunov D.Y., Smirnov Y.A., Naroditsky B.S., Gintsburg A.L. Induction of a protective heterosubtypic immune response against the influenza virus by using recombinant adenoviral vectors expressing hemagglutinin of the influenza H5 virus. Acta Naturae 2010, 2:111-118.
55. Shukla A.A., Thömmes J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010, 28:253-261.
56. Smirnov Y.A., Lipatov A.S., Van Beek R., Gitelman A.K., Osterhaus A.D., Claas E.C. Characterization of adaptation of an avian influenza A (H5N2) virus to a mammalian host. Acta Virol. 2000, 44:1-8.
57. Sofer-Podesta C., Ang J., Hackett N.R., Senina S., Perlin D., Crystal R.G., Boyer J.L. Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge. Infect. Immunol. 2009, 77:1561-1568.
58. Song J.M., Wang B.Z., Park K.M., Van Rooijen N., Quan F.S., Kim M.C., Jin H.T., Pekosz A., Compans R.W., Kang S.M. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 2011, 6:e14538.
59. Sorger P.K., Nelson H.C. Trimerization of a yeast transcriptional activator via a coiled-coil motif. Cell 1989, 59:807-813.
60. Staneková Z., Varečková E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol. J. 2010, 7:351.
61. Stone D., Ni S., Li Z.Y., Gaggar A., DiPaolo N., Feng Q., Sandig V., Lieber A. Development and assessment of human adenovirus type 11 as a gene transfer vector. J. Virol. 2005, 79:5090-5104.
62. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., Santelli E., Stec B., Cadwell G., Ali M., Wan H., Murakami A., Yammanuru A., Han T., Cox N.J., Bankston L.A., Donis R.O., Liddington R.C., Marasco W.A. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 2009, 16:265-273.
63. Szretter K.J., Balish A.L., Katz J.M. Influenza: propagation, quantification, and storage. Curr. Protoc. Microbiol. 2006, 3. 15G.1.1-15G.1.22.
64. Tani J., Faustine, Sufian J.T. Updates on current advances in gene therapy. West Indian Med. J. 2011, 60:188-194.
65. Thacker E.E., Timares L., Matthews Q.L. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert. Rev. Vaccines 2009, 8:761-777.
66. Throsby M., van den Brink E., Jongeneelen M., Poon L.L., Alard P., Cornelissen L., Bakker A., Cox F., van Deventer E., Guan Y., Cinatl J., terMeulen J., Lasters I., Carsetti R., Peiris M., de Kruif J., Goudsmit J. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008, 3:e3942.
67. Tillib S.V., Ivanova T.I., Vasilev L.A. Fingerprint-like analysis of "nanoantibody" selection by phage display using two helper phage variants. Acta Naturae 2010, 2:85-93.
68. Tillib S.V. "Camel nanoantibody" is an efficient tool for research, diagnostics and therapy. Mol. Biol. (Mosk) 2011, 45:77-85.
69. Tutykhina I.L., Bezborodova O.A., Verkhovskaia L.V., Shmarov M.M., Logunov D.I., Nemtsova E.R., Narodnotskiǐ B.S., Iakubovskaia R.I., Gintsburg A.L. Recombinant pseudoadenovirus nanostructure with human lactoferrin gene: production and study of lactoferrin expression and properties in vivo usage of the construction. Mol. Gen. Mikrobiol. Virusol. 2009, 1:27-31.
70. Vanlandschoot P., Stortelers C., Beirnaert E., Ibañez L.I., Schepens B., Depla E., Saelens X. Nanobodies®: new ammunition to battle viruses. Antiviral Res. 2011, 92:389-407.
71. Vincke C., Loris R., Saerens D., Martinez-Rodriguez S., Muyldermans S., Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 2009, 284:3273-3284.
72. Weaver E.A., Barry M.A. Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum. Gene Ther. 2008, 19:1369-1382.
73. Wei G., Meng W., Guo H., Pan W., Liu J., Peng T., Chen L., Chen C.Y. Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein. PLoS One 2011, 6:e28309.
74. Wesolowski J., Alzogaray V., Reyelt J., Unger M., Juarez K., Urrutia M., Cauerhff A., Danquah W., Rissiek B., Scheuplein F., Schwarz N., Adriouch S., Boyer O., Seman M., Licea A., Serreze D.V., Goldbaum F.A., Haag F., Koch-Nolte F. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol. 2009, 198:157-174.
75. Wilson J.M. Adenoviruses as gene-delivery vehicles. N. Engl. J. Med. 1996, 334:1185-1187.
76. Ye J., Shao H., Perez D.R. Passive immune neutralization strategies for prevention and control of influenza A infections. Immunotherapy 2012, 4:175-186.
77. Zuber C., Mitteregger G., Schuhmann N., Rey C., Knackmuss S., Rupprecht W., Reusch U., Pace C., Little M., Kretzschmar H.A., Hallek M., Büning H., Weiss S. Delivery of single-chain antibodies (scFvs) directed against the 37/67kD alaminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J. Gen. Virol. 2008, 89:2055-2061.